Short answer
Insmed Incorporated (INSM) filed an 8-K current report with the SEC on October 20, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expansion effective October 19, 2026: Paul Hudson, Class II, and Utpal Koppikar, Class I, stand for election in 2027.
Insmed Incorporated 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expansion effective October 19, 2026: Paul Hudson, Class II, and Utpal Koppikar, Class I, stand for election in 2027
- Hudson adds global biopharma CEO experience, including Sanofi and Novartis Pharmaceuticals leadership
- Koppikar adds senior biopharma finance expertise, currently serving as Verily CFO
- Committee assignments strengthen oversight: Hudson joins Compensation, Koppikar joins Audit
- Each director receives $65,000 annual cash, $12,500 committee retainer, and approximately $585,000 in RSUs vesting over three years
Item 7.01 · Regulation FD Disclosure
- Press release announces appointments of Mr. Hudson and Mr. Koppikar
- Leadership changes may affect strategic execution and investor expectations
- Exhibit 99.1 contains the appointees’ titles, backgrounds and effective dates
Item EX-99.1 · Exhibit EX-99.1
- Paul Hudson, former Sanofi and Novartis Pharmaceuticals CEO, appointed independent director effective immediately
- Utpal Koppikar, Verily CFO and former Atara Biotherapeutics CFO, appointed independent director effective immediately
- Board additions strengthen global commercialization, strategic transformation, financial management, and biopharma scaling expertise
- Appointments support Insmed’s growth strategy as it advances approved therapies and mid- to late-stage pipeline programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Insmed Incorporated 8-K filings
Get the next INSM 8-K as it lands
Follow INSM for push alerts, or ask the research agent what this filing means.